Helix BioPharma Corp. (HBP.TO)
CAD 0.78
(0.0%)
CAD 0.78
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 1.57 Million CAD | -15.7% |
| 2023 | 1.87 Million CAD | -45.09% |
| 2022 | 3.41 Million CAD | -37.5% |
| 2021 | 5.45 Million CAD | 183.53% |
| 2020 | 1.92 Million CAD | -54.39% |
| 2019 | 4.22 Million CAD | 57.85% |
| 2018 | 2.67 Million CAD | 21.32% |
| 2017 | 2.2 Million CAD | 69.02% |
| 2016 | 1.3 Million CAD | 34.57% |
| 2015 | 969 Thousand CAD | -7.01% |
| 2014 | 1.04 Million CAD | 9.92% |
| 2013 | 948 Thousand CAD | -31.9% |
| 2012 | 1.39 Million CAD | -38.35% |
| 2011 | 2.25 Million CAD | -4.04% |
| 2010 | 2.35 Million CAD | 4.3% |
| 2009 | 2.25 Million CAD | 97.2% |
| 2008 | 1.14 Million CAD | -25.67% |
| 2007 | 1.53 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 603 Thousand CAD | -52.63% |
| 2024 Q1 | 1.27 Million CAD | -32.03% |
| 2024 Q3 | 1.5 Million CAD | 149.59% |
| 2024 Q4 | 1.57 Million CAD | 4.92% |
| 2023 Q3 | 673 Thousand CAD | -30.83% |
| 2023 Q4 | 1.87 Million CAD | 178.31% |
| 2023 FY | 1.87 Million CAD | -45.09% |
| 2023 Q1 | 5.66 Million CAD | 66.11% |
| 2023 Q2 | 973 Thousand CAD | -82.83% |
| 2022 Q4 | 3.41 Million CAD | -19.91% |
| 2022 FY | 3.41 Million CAD | -37.5% |
| 2022 Q1 | 5.04 Million CAD | -7.6% |
| 2022 Q2 | 5.03 Million CAD | -0.14% |
| 2022 Q3 | 4.25 Million CAD | -15.43% |
| 2021 Q1 | 1.98 Million CAD | 2.96% |
| 2021 FY | 5.45 Million CAD | 183.53% |
| 2021 Q2 | 1.23 Million CAD | -37.69% |
| 2021 Q3 | 1.71 Million CAD | 38.7% |
| 2021 Q4 | 5.45 Million CAD | 218.62% |
| 2020 Q1 | 1.76 Million CAD | -58.09% |
| 2020 FY | 1.92 Million CAD | -54.39% |
| 2020 Q4 | 1.92 Million CAD | 18.32% |
| 2020 Q2 | 1.65 Million CAD | -6.67% |
| 2020 Q3 | 1.62 Million CAD | -1.45% |
| 2019 FY | 4.22 Million CAD | 57.85% |
| 2019 Q1 | 3.43 Million CAD | 28.31% |
| 2019 Q2 | 2.88 Million CAD | -16.03% |
| 2019 Q3 | 3.51 Million CAD | 22.15% |
| 2019 Q4 | 4.22 Million CAD | 19.95% |
| 2018 Q2 | 2.49 Million CAD | 26.75% |
| 2018 Q1 | 1.96 Million CAD | -10.8% |
| 2018 FY | 2.67 Million CAD | 21.32% |
| 2018 Q4 | 2.67 Million CAD | -16.98% |
| 2018 Q3 | 3.22 Million CAD | 29.25% |
| 2017 Q1 | 2.34 Million CAD | 79.52% |
| 2017 Q2 | 2.67 Million CAD | 14.31% |
| 2017 FY | 2.2 Million CAD | 69.02% |
| 2017 Q4 | 2.2 Million CAD | -41.51% |
| 2017 Q3 | 3.76 Million CAD | 40.81% |
| 2016 Q2 | 1 Million CAD | -26.61% |
| 2016 FY | 1.3 Million CAD | 34.57% |
| 2016 Q4 | 1.3 Million CAD | -9.82% |
| 2016 Q3 | 1.44 Million CAD | 44.02% |
| 2016 Q1 | 1.36 Million CAD | 41.18% |
| 2015 Q2 | 1.17 Million CAD | 46.2% |
| 2015 FY | 969 Thousand CAD | -7.01% |
| 2015 Q1 | 803 Thousand CAD | -22.94% |
| 2015 Q4 | 969 Thousand CAD | -13.87% |
| 2015 Q3 | 1.12 Million CAD | -4.17% |
| 2014 Q3 | 650 Thousand CAD | 26.46% |
| 2014 FY | 1.04 Million CAD | 9.92% |
| 2014 Q2 | 514 Thousand CAD | -41.52% |
| 2014 Q1 | 879 Thousand CAD | -7.28% |
| 2014 Q4 | 1.04 Million CAD | 60.31% |
| 2013 Q4 | 948 Thousand CAD | -28.13% |
| 2013 FY | 948 Thousand CAD | -31.9% |
| 2013 Q1 | 1.58 Million CAD | 13.86% |
| 2013 Q2 | 1.27 Million CAD | -19.43% |
| 2013 Q3 | 1.31 Million CAD | 3.29% |
| 2012 Q3 | 1.88 Million CAD | -64.25% |
| 2012 Q2 | 5.27 Million CAD | 122.43% |
| 2012 FY | 1.39 Million CAD | -38.35% |
| 2012 Q4 | 1.39 Million CAD | -26.19% |
| 2012 Q1 | 2.37 Million CAD | 5.05% |
| 2011 FY | 2.25 Million CAD | -4.04% |
| 2011 Q4 | 2.25 Million CAD | 0.0% |
| 2010 FY | 2.35 Million CAD | 4.3% |
| 2009 FY | 2.25 Million CAD | 97.2% |
| 2008 FY | 1.14 Million CAD | -25.67% |
| 2007 FY | 1.53 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | 87.282% |
| Eupraxia Pharmaceuticals Inc. | 25.54 Million CAD | 93.819% |
| Microbix Biosystems Inc. | 11.02 Million CAD | 85.683% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | 88.675% |
| Satellos Bioscience Inc. | 3.62 Million CAD | 56.429% |
| Oncolytics Biotech Inc. | 11.25 Million CAD | 85.973% |
| Sernova Corp. | 9.59 Million CAD | 83.539% |